This prolonged survival under sequential high-dose third-generation EGFR-TKI therapy is notable in the context of EGFR exon 20 insertion-mutant NSCLC and underpins the hypothesis-generating nature of this report. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.